Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Ribupatide, KAI-9531
Ribupatide (KAI-9531) · 5 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| Ribupatide: Dose 1 | EXPERIMENTAL | Participants will receive Dose 1 of ribupatide once weekly. |
| Ribupatide: Dose 2 | EXPERIMENTAL | Participants will receive Dose 2 of ribupatide once weekly. |
| Ribupatide: Dose 3 | EXPERIMENTAL | Participants will receive Dose 3 of ribupatide once weekly. |
| Ribupatide: Dose 4 | EXPERIMENTAL | Participants will receive Dose 4 of ribupatide once weekly. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matched to ribupatide once weekly. |
| Semaglutide | ACTIVE_COMPARATOR | Participants will receive semaglutide once weekly. |
| Ribupatide | EXPERIMENTAL | Participants will receive ribupatide once weekly. |
| Name | Type | Description |
|---|---|---|
| Ribupatide | DRUG | SC Injection |
| Placebo | DRUG | SC Injection |
| Semaglutide | DRUG | SC Injection |
Key Inclusion Criteria: * Diagnosis of type 2 diabetes mellitus (T2DM). * Receiving stable therapy for T2DM for 3 months prior to Screening. This includes diet and/or exercise alone or in combination with any oral medication for T2DM treatment except for DPP-4 inhibitors. Participants can be treatm...
Top 20 of 37 competitors
Ribupatide, also known as KAI-9531, is an investigational small molecule developed by Kailera Therapeutics for metabolic conditions. It is being studied in obesity, obesity with diabetes, and end stage renal disease. It is a peptide-class agent that targets the GLP-1 and GIP receptors and is given once weekly in the obesity trials.
Ribupatide targets the GLP-1 and GIP receptors. It is a peptide-class molecule that engages both incretin receptors, and the obesity studies administer it once weekly. Targeting both GLP-1 and GIP places it among dual incretin receptor agonists being developed for metabolic disease.
Ribupatide is being developed by Kailera Therapeutics, Inc., which trades under the ticker KLRA. The company is running the clinical program for the drug across obesity, obesity with diabetes, and renal impairment settings, with trials conducted in the United States and several additional countries.
Ribupatide is in clinical development across multiple phases. A Phase 1 pharmacokinetic study in renal impairment is recruiting, while two Phase 3 obesity trials and one Phase 2 obesity trial are active but not recruiting. Ribupatide is investigational and has not been approved by the FDA.
Ribupatide is being studied in NCT07793929, a Phase 1 pharmacokinetic trial in renal impairment with 32 participants, and NCT07458269, a Phase 2 obesity trial with 264 participants. Two Phase 3 obesity trials are also underway: NCT07284979 comparing ribupatide with semaglutide and placebo, and NCT07284901 in obesity or overweight with diabetes, each enrolling 1,270 participants.
Yes, ribupatide and KAI-9531 refer to the same investigational drug from Kailera Therapeutics. Ribupatide is the name used in trial titles, and KAI-9531 appears alongside it in the company's study listings, so searches for either name lead to the same clinical program in obesity and related metabolic conditions.